ArticleJAMA network open2026
Comparative Risk of Hyponatremia Among Patients Treated With Second-Generation Antipsychotics.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Hyponatremia is an adverse event associated with antipsychotic use; however, comparative evidence among individual second-generation antipsychotics remains limited. Objective: To compare the risk of hyponatremia associated with individual second-generation antipsychotics. Design, Setting, and Participants: In this retrospective cohort study and disproportionality analysis, data were obtained from the US Food and Drug Administration Adverse Event Reporting System (FAERS; quarter 4 1997 to quarter 3 2023), a dataset provided by the Japan Pharmaceutical Information Center, and a Japanese hospital-based claims database (Medical Data Vision; April 2008 to April 2024). The study adopted a new-user design and included patients routinely prescribed antipsychotics. Patients aged 18 to 69 years with at least 180 days of active medical history preceding the initial antipsychotic prescription, with no history of antipsychotics or hyponatremia during that period, were included. Exposures: Initiation of second-generation antipsychotics. Main Outcomes and Measures: Hyponatremia associated with individual antipsychotics was compared with that associated with olanzapine. Reporting odds ratios with 95% CIs were calculated for FAERS. The incidence within 180 days of treatment initiation was analyzed for claims database using hazard ratios estimated with stabilized inverse probability of treatment weighting based on propensity scores. Results: In the FAERS database, most antipsychotics showed lower reporting odds ratios for hyponatremia than olanzapine. In a Japanese claims database, among 961 010 patients prescribed antipsychotics, 55 394 were included in the final analysis. The mean (SD) age was 50.4 (14.3) years, and there were 25 839 (46.6%) male and 29 555 (53.4%) female patients. After stabilized inverse probability of treatment weighting, aripiprazole was associated with a significantly lower risk of hyponatremia than olanzapine (adjusted hazard ratio, 0.52; 95% CI, 0.35-0.76), whereas other antipsychotics showed no significant differences. Sensitivity analysis confirmed the robustness of the findings. Conclusions and Relevance: In this retrospective cohort study of antipsychotic users, aripiprazole was associated with a lower risk of hyponatremia than was olanzapine. Although residual confounding should be considered, these findings may help inform clinical decision-making for high-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.